TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05096481: PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

Sponsor: Nationwide Children's Hospital · Phase: PHASE2 · Area: INFECTIOUS_VACCINE · Target Enrollment: 120 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$1,440,600

Rescue Site Savings

+$940,800

Unlock Full NCT05096481 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05096481 Rescue Dossier →